Binding of Rac1, Rnd1, and RhoD to a novel Rho GTPase interaction motif destabilizes dimerization of the plexin-B1 effector domain

Department of Physiology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Journal of Biological Chemistry (Impact Factor: 4.6). 01/2008; 282(51):37215-24. DOI: 10.1074/jbc.M703800200
Source: PubMed

ABSTRACT Plexins are the first known transmembrane receptors that interact directly with small GTPases. On binding to certain Rho family GTPases, the receptor regulates the remodeling of the actin cytoskeleton and alters cell movement in response to semaphorin guidance cues. In a joint solution NMR spectroscopy and x-ray crystallographic study, we characterize a 120-residue cytoplasmic independent folding domain of plexin-B1 that directly binds three Rho family GTPases, Rac1, Rnd1, and RhoD. The NMR data show that, surprisingly, the Cdc42/Rac interactive binding-like motif of plexin-B1 is not involved in this interaction. Instead, all three GTPases interact with the same region, beta-strands 3 and 4 and a short alpha-helical segment of the plexin domain. The 2.0 A resolution x-ray structure shows that these segments are brought together by the tertiary structure of the ubiquitin-like fold. In the crystal, the protein is dimerized with C2 symmetry through a four-stranded antiparallel beta-sheet that is formed outside the fold by a long loop between the monomers. This region is adjacent to the GTPase binding motifs identified by NMR. Destabilization of the dimer in solution by binding of any one of the three GTPases suggests a model for receptor regulation that involves bidirectional signaling. The model implies a multifunctional role for the GTPase-plexin interaction that includes conformational change and a localization of active receptors in the signaling mechanism.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Repulsive signaling by Semaphorins and Plexins is crucial for the development and homeostasis of the nervous, immune, and cardiovascular systems. Sema7A acts as both an immune and a neural Semaphorin through PlexinC1, and A39R is a Sema7A mimic secreted by smallpox virus. We report the structures of Sema7A and A39R complexed with the Semaphorin-binding module of PlexinC1. Both structures show two PlexinC1 molecules symmetrically bridged by Semaphorin dimers, in which the Semaphorin and PlexinC1 beta propellers interact in an edge-on, orthogonal orientation. Both binding interfaces are dominated by the insertion of the Semaphorin's 4c-4d loop into a deep groove in blade 3 of the PlexinC1 propeller. A39R appears to achieve Sema7A mimicry by preserving key Plexin-binding determinants seen in the mammalian Sema7A complex that have evolved to achieve higher affinity binding to the host-derived PlexinC1. The complex structures support a conserved Semaphorin-Plexin recognition mode and suggest that Plexins are activated by dimerization.
    Cell 09/2010; 142(5):749-61. DOI:10.1016/j.cell.2010.07.040 · 33.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is one of the most common cancers in the Western world. The metastasis of prostate cancer cells is the major cause of prostate cancer-related death. Understanding which genes are altered in prostate cancer and their implications for cell signaling and function is crucial for designing therapy strategies. Our group has identified a high frequency of somatic missense mutations in the plexin-B1 gene in localized and metastatic prostate cancer. The mutations are correlated with elevated metastatic features such as increased cell invasion, adhesion and decreased cell collapse relative to wildtype. Given the fact that Sema4D/plexin-B1 regulates cell signaling through coupling with tyrosine kinases and small GTPases, I hypothesized that plexin-B1 mutations may contribute to prostate cancer cell progression through affecting these pathways. The aims of this study were to characterize the molecular features of the three mutated forms of plexin-B1, A5359G, A5653G, and T5714C and to determine how the mutations affect cell signaling. It was found, using co-immunoprecipitation assays, that none of the three mutations affected the binding of either ErbB-2 or Met to plexin-B1. Sema4D/plexin-B1 mediated cell motility depending on the stoichiometry of plexin-B1, ErbB-2 and Met in prostate cancer cells. In addition, positive evidence was found for the impact of wildtype and mutant plexin-B1 on PI3K/Akt and MAPK pathways. All the three mutants exhibited an increased binding ability to RhoD GTPase relative to wildtype in GST-pulldown assays. This increased binding to RhoD is also associated with increased cell motility as shown in transwell migration assays. My study suggests that the three mutants confer a gain of metastatic phenotype to the cells through inactivating inhibitory pathways and has lead to the construction of a new model describing the mechanism by which plexin-B1 mutations contribute to cancer progression.


Available from